Log-in
Sign-up
Webcast
Clinical Trials
Webcast
Clinical Trials
Home
>
Clinical Trials
Molecules
전체
Edoxaban
Olmesartan
Prasugrel
Pravastatin
Mirogabalin
Ramosetron
Trastuzumab deruxtecan
Status
Select
Check All
Search
Recruiting
Completed
Not yet recruiting
Enrolling by invitation
Active, not recruiting
Suspended
Terminated
Withdrawn
Unknown status
Email
Saved trials
RECRUITING
NCT05845450
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
112
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE2)
Colorectal Cancer
Resectable Colorectal Carcinoma
ACTIVE_NOT_RECRUITING
NCT05744375
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
2
Enrollment(s)
19
Study location(s)
INTERVENTIONAL (PHASE2)
Locally Advanced Breast Cancer
Metastatic Breast Cancer
RECRUITING
NCT05704829
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
402
Enrollment(s)
43
Study location(s)
INTERVENTIONAL (PHASE2)
HER2-positive Early Breast Cancer
RECRUITING
NCT05681702
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
90
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE4)
Coronary Artery Disease
ACTIVE_NOT_RECRUITING
NCT05660135
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia
4,000
Enrollment(s)
1
Study location(s)
OBSERVATIONAL (None)
Hypertension
Dyslipidemias
RECRUITING
NCT05650879
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
198
Enrollment(s)
39
Study location(s)
INTERVENTIONAL (PHASE1)
HER2 Mutant Non-small Cell Lung Cancer
HER2-positive Metastatic Breast Cancer
HER2 Gene Mutation
HER2 Amplification
RECRUITING
NCT05633979
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
37
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE1)
Breast Cancer
RECRUITING
NCT05573893
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
800
Enrollment(s)
91
Study location(s)
OBSERVATIONAL (None)
Breast Neoplasms
Breast Cancer
Neoplasm Metastasis
11
12
13
14
15